BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology. 1997;113:1264-1269. [PMID: 9322521 DOI: 10.1053/gast.1997.v113.pm9322521] [Cited by in Crossref: 228] [Cited by in F6Publishing: 171] [Article Influence: 9.1] [Reference Citation Analysis]
Number Citing Articles
1 Weinrieb RM, Van Horn DH, Mclellan AT, Alterman AI, Calarco JS, O’brien CP, Lucey MR. Alcoholism Treatment After Liver Transplantation: Lessons Learned From a Clinical Trial That Failed. Psychosomatics 2001;42:110-6. [DOI: 10.1176/appi.psy.42.2.110] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 2.8] [Reference Citation Analysis]
2 Bergasa NV. Lysophosphatidic acid and atotaxin in patients with cholestasis and pruritus: Fine biology, anticipated discernment. Annals of Hepatology 2010;9:475-9. [DOI: 10.1016/s1665-2681(19)31629-1] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
3 Bergasa NV. The pruritus of cholestasis: From bile acids to opiate agonists: Relevant after all these years. Medical Hypotheses 2018;110:86-9. [DOI: 10.1016/j.mehy.2017.11.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
4 Bolier R, Oude Elferink RP, Beuers U. Advances in pathogenesis and treatment of pruritus. Clin Liver Dis. 2013;17:319-329. [PMID: 23540505 DOI: 10.1016/j.cld.2012.11.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
5 Bigliardi PL, Stammer H, Jost G, Rufli T, Büchner S, Bigliardi-qi M. Treatment of pruritus with topically applied opiate receptor antagonist. Journal of the American Academy of Dermatology 2007;56:979-88. [DOI: 10.1016/j.jaad.2007.01.007] [Cited by in Crossref: 80] [Cited by in F6Publishing: 67] [Article Influence: 5.3] [Reference Citation Analysis]
6 Marzioni M, Svegliati Baroni G, Alpini G, Benedetti A. Endogenous opioid peptides and chronic liver disease: from bedside to bench. J Hepatol 2007;46:583-6. [PMID: 17313989 DOI: 10.1016/j.jhep.2007.01.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
7 Costamagna G, Familiari P, Tringali A, Mutignani M. Multidisciplinary approach to benign biliary strictures. Curr Treat Options Gastro 2007;10:90-101. [DOI: 10.1007/s11938-007-0061-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
8 Hamilton JP, Laurin JM. Drug-Induced Cholestasis. In: Lindor KD, Talwalkar JA, editors. Cholestatic Liver Disease. Totowa: Humana Press; 2008. pp. 21-43. [DOI: 10.1007/978-1-59745-118-5_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
9 Siemens W, Xander C, Meerpohl JJ, Buroh S, Antes G, Schwarzer G, Becker G. Pharmacological interventions for pruritus in adult palliative care patients. Cochrane Database Syst Rev 2016;11:CD008320. [PMID: 27849111 DOI: 10.1002/14651858.CD008320.pub3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
10 Düll MM, Kremer AE. Treatment of Pruritus Secondary to Liver Disease. Curr Gastroenterol Rep 2019;21. [DOI: 10.1007/s11894-019-0713-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
11 Sinakos E, Lindor K. Treatment options for primary sclerosing cholangitis. Expert Review of Gastroenterology & Hepatology 2014;4:473-88. [DOI: 10.1586/egh.10.33] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
12 Prince MI, Mitchison HC, Ashley D, Burke DA, Edwards N, Bramble MG, James OF, Jones DE. Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, cross-over trial. Aliment Pharmacol Ther. 2003;17:137-143. [PMID: 12492743 DOI: 10.1046/j.1365-2036.2003.01398.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 1.8] [Reference Citation Analysis]
13 Bassari R, Koea JB. Jaundice associated pruritis: A review of pathophysiology and treatment. World J Gastroenterol 2015; 21(5): 1404-1413 [PMID: 25663760 DOI: 10.3748/wjg.v21.i5.1404] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
14 Kambia NK, Dine T, Odou P, Bah S, Azar R, Gressier B, Dupin-spriet T, Luyckx M, Brunet C. Pharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis. European Journal of Drug Metabolism and Pharmacokinetics 2004;29:225-30. [DOI: 10.1007/bf03190603] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Pereira MP, Ständer S. Therapy for pruritus in the elderly: a review of treatment developments. Expert Opinion on Pharmacotherapy 2018;19:443-50. [DOI: 10.1080/14656566.2018.1444752] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
16 Tajiri K, Shimizu Y. Recent advances in the management of pruritus in chronic liver diseases. World J Gastroenterol 2017; 23(19): 3418-3426 [PMID: 28596678 DOI: 10.3748/wjg.v23.i19.3418] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
17 Jones EA, Bergasa NV. The pruritus of cholestasis. Hepatology. 1999;29:1003-1006. [PMID: 10094938 DOI: 10.1002/hep.510290450] [Cited by in Crossref: 117] [Cited by in F6Publishing: 91] [Article Influence: 5.1] [Reference Citation Analysis]
18 Neff GW, O'Brien CB, Reddy KR, Bergasa NV, Regev A, Molina E, Amaro R, Rodriguez MJ, Chase V, Jeffers L, Schiff E. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol. 2002;97:2117-2119. [PMID: 12190187 DOI: 10.1111/j.1572-0241.2002.05852.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 62] [Article Influence: 4.4] [Reference Citation Analysis]
19 Bergasa NV, Jones EA. THE PRURITUS OF CHOLESTASIS. Clinics in Liver Disease 1998;2:391-405. [DOI: 10.1016/s1089-3261(05)70014-3] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
20 Trivedi HD, Lizaola B, Tapper EB, Bonder A. Management of Pruritus in Primary Biliary Cholangitis: A Narrative Review. The American Journal of Medicine 2017;130:744.e1-7. [DOI: 10.1016/j.amjmed.2017.01.037] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
21 Davis M. Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics. Clin Pharmacokinet 2007;46:825-50. [PMID: 17854233 DOI: 10.2165/00003088-200746100-00002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
22 Trauner M, Boyer JL. Cholestatic syndromes: . Current Opinion in Gastroenterology 1999;15:217-28. [DOI: 10.1097/00001574-199905000-00006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
23 Murray-Brown FL. Naltrexone for cholestatic itch: a systematic review. BMJ Support Palliat Care 2021;11:217-25. [PMID: 33692114 DOI: 10.1136/bmjspcare-2020-002801] [Reference Citation Analysis]
24 Parés A, Cisneros L, Salmerón JM, Caballería L, Mas A, Torras A, Rodés J. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol. 2004;99:1105-1110. [PMID: 15180733 DOI: 10.1111/j.1572-0241.2004.30204.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 62] [Article Influence: 4.3] [Reference Citation Analysis]
25 Mettang T, Streit M, Weisshaar E. Pruritus bei inneren Erkrankungen. Hautarzt 2006;57:395-402. [DOI: 10.1007/s00105-006-1124-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
26 Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009;50:291-308. [PMID: 19554543 DOI: 10.1002/hep.22906] [Cited by in Crossref: 850] [Cited by in F6Publishing: 705] [Article Influence: 65.4] [Reference Citation Analysis]
27 Glasova H, Beuers U. Extrahepatic manifestations of cholestasis. Journal of Gastroenterology and Hepatology 2002;17:938-48. [DOI: 10.1046/j.1440-1746.2002.02717.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
28 Silveira MG, Lindor KD. Primary sclerosing cholangitis. Can J Gastroenterol 2008;22:689-98. [PMID: 18701947 DOI: 10.1155/2008/824168] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 3.6] [Reference Citation Analysis]
29 Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. Journal of the American Academy of Dermatology 2006;54:527-31. [DOI: 10.1016/j.jaad.2005.12.010] [Cited by in Crossref: 120] [Cited by in F6Publishing: 83] [Article Influence: 7.5] [Reference Citation Analysis]
30 Ko MCH, Song MS, Edwards T, Lee H, Naughton NN. The Role of Central μ Opioid Receptors in Opioid-Induced Itch in Primates. J Pharmacol Exp Ther 2004;310:169-76. [DOI: 10.1124/jpet.103.061101] [Cited by in Crossref: 95] [Cited by in F6Publishing: 83] [Article Influence: 5.3] [Reference Citation Analysis]
31 Bonacini M. Pruritus in patients with chronic human immunodeficiency virus, hepatitis B and C virus infections. Dig Liver Dis. 2000;32:621-625. [PMID: 11142563 DOI: 10.1016/s1590-8658(00)80847-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
32 Yerushalmi B, Sokol RJ, Narkewicz MR, Smith D, Karrer FM. Use of rifampin for severe pruritus in children with chronic cholestasis. J Pediatr Gastroenterol Nutr 1999;29:442-7. [PMID: 10512405 DOI: 10.1097/00005176-199910000-00013] [Cited by in Crossref: 73] [Cited by in F6Publishing: 53] [Article Influence: 3.2] [Reference Citation Analysis]
33 McRae CA, Prince MI, Hudson M, Day CP, James OF, Jones DE. Pain as a complication of use of opiate antagonists for symptom control in cholestasis. Gastroenterology 2003;125:591-6. [PMID: 12891561 DOI: 10.1016/s0016-5085(03)00879-5] [Cited by in Crossref: 55] [Cited by in F6Publishing: 10] [Article Influence: 2.9] [Reference Citation Analysis]
34 Greaves MW. Itch in systemic disease: therapeutic options: Itch in systemic disease. Dermatologic Therapy 2005;18:323-7. [DOI: 10.1111/j.1529-8019.2005.00036.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
35 Terán A, Fábrega E, Pons-Romero F. [Pruritus associated with cholestasis]. Gastroenterol Hepatol 2010;33:313-22. [PMID: 19836105 DOI: 10.1016/j.gastrohep.2009.07.006] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
36 Bergasa NV, McGee M, Ginsburg IH, Engler D. Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2006;44:1317-1323. [PMID: 17058231 DOI: 10.1002/hep.21370] [Cited by in Crossref: 69] [Cited by in F6Publishing: 45] [Article Influence: 4.3] [Reference Citation Analysis]
37 Schmelz M. Itch—mediators and mechanisms. Journal of Dermatological Science 2002;28:91-6. [DOI: 10.1016/s0923-1811(01)00167-0] [Cited by in Crossref: 77] [Cited by in F6Publishing: 7] [Article Influence: 3.9] [Reference Citation Analysis]
38 Brasileiro LE, Barreto DP, Nunes EA. Psychotropics in different causes of itch: systematic review with controlled studies. An Bras Dermatol 2016;91:791-8. [PMID: 28099602 DOI: 10.1590/abd1806-4841.20164878] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
39 Lee J, Shin JU, Noh S, Park CO, Lee KH. Clinical Efficacy and Safety of Naltrexone Combination Therapy in Older Patients with Severe Pruritus. Ann Dermatol 2016;28:159-63. [PMID: 27081261 DOI: 10.5021/ad.2016.28.2.159] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
40 Shah NM, Malhotra AM, Kaltsakas G. Sleep disorder in patients with chronic liver disease: a narrative review. J Thorac Dis 2020;12:S248-60. [PMID: 33214928 DOI: 10.21037/jtd-cus-2020-012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
41 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67:145-172. [PMID: 28427765 DOI: 10.1016/j.jhep.2017.03.022] [Cited by in Crossref: 409] [Cited by in F6Publishing: 326] [Article Influence: 81.8] [Reference Citation Analysis]
42 Sanjel B, Shim WS. Recent advances in understanding the molecular mechanisms of cholestatic pruritus: A review. Biochim Biophys Acta Mol Basis Dis 2020;1866:165958. [PMID: 32896605 DOI: 10.1016/j.bbadis.2020.165958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Etter L, Myers SA. Pruritus in systemic disease: mechanisms and management. Dermatologic Clinics 2002;20:459-72. [DOI: 10.1016/s0733-8635(02)00011-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
44 Leckie P, Tritto G, Mookerjee R, Davies N, Jones D, Jalan R. ‘Out-patient’ albumin dialysis for cholestatic patients with intractable pruritus. Letters to the Editors 2012;35:696-704. [DOI: 10.1111/j.1365-2036.2012.04994.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
45 Huang CS, Lichtenstein DR. Treatment of Biliary Problems in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2005;8:117-26. [PMID: 15769433 DOI: 10.1007/s11938-005-0004-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
46 Kunzmann S, Kullak-ublick GA, Greiner A, Jeschke R, Hebestreit H. Effective Opiate-Receptor Antagonist Therapy of Cholestatic Pruritus Induced by an Oral Contraceptive: . Journal of Pediatric Gastroenterology and Nutrition 2005;40:596-9. [DOI: 10.1097/01.mpg.0000148775.64966.96] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Angulo P, Lindor KD. PRIMARY BILIARY CIRRHOSIS AND PRIMARY SCLEROSING CHOLANGITIS. Clinics in Liver Disease 1999;3:529-70. [DOI: 10.1016/s1089-3261(05)70084-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
48 Terra SG, Tsunoda SM. Opioid antagonists in the treatment of pruritus from cholestatic liver disease. Ann Pharmacother 1998;32:1228-30. [PMID: 9825091 DOI: 10.1345/aph.18115] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
49 Steinhoff M, Cevikbas F, Ikoma A, Berger TG. Pruritus: management algorithms and experimental therapies. Semin Cutan Med Surg 2011;30:127-37. [PMID: 21767775 DOI: 10.1016/j.sder.2011.05.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
50 Bergasa NV, Jones EA. Assessment of the Visual Analogue Score in the Evaluation of the Pruritus of Cholestasis. J Clin Transl Hepatol 2017;5:203-7. [PMID: 28936401 DOI: 10.14218/JCTH.2017.00001] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
51 Lasalle L, Rachelska G, Nedelec B. Naltrexone for the management of post-burn pruritus: A preliminary report. Burns 2008;34:797-802. [DOI: 10.1016/j.burns.2007.10.009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
52 Tennyson H, Levine N. NEUROTROPIC AND PSYCHOTROPIC DRUGS IN DERMATOLOGY. Dermatologic Clinics 2001;19:179-97. [DOI: 10.1016/s0733-8635(05)70239-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
53 Golpanian RS, Yosipovitch G. Current and emerging systemic treatments targeting the neural system for chronic pruritus. Expert Opin Pharmacother 2020;21:1629-36. [PMID: 32515664 DOI: 10.1080/14656566.2020.1775815] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
54 Bosonnet L. Pruritus: scratching the surface. Eur J Cancer Care (Engl). 2003;12:162-165. [PMID: 12787014 DOI: 10.1046/j.1365-2354.2003.00395.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
55 Grundmann SA, Ständer S. Evaluation of chronic pruritus in older patients. Aging Health 2010;6:53-66. [DOI: 10.2217/ahe.09.84] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
56 Worthington J, Chapman R. Primary sclerosing cholangitis. Orphanet J Rare Dis 2006;1:41. [PMID: 17062136 DOI: 10.1186/1750-1172-1-41] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
57 Sanchez W, Talwalkar JA. Palliative care for patients with end-stage liver disease ineligible for liver transplantation. Gastroenterol Clin North Am 2006;35:201-19. [PMID: 16530121 DOI: 10.1016/j.gtc.2005.12.007] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
58 Patel AD, Katz K, Gordon KB. Cutaneous Manifestations of Chronic Liver Disease. Clin Liver Dis 2020;24:351-60. [PMID: 32620276 DOI: 10.1016/j.cld.2020.04.003] [Reference Citation Analysis]
59 Razykov I, Levis B, Hudson M, Baron M, Thombs BD. Prevalence and clinical correlates of pruritus in patients with systemic sclerosis: an updated analysis of 959 patients. Rheumatology 2013;52:2056-61. [DOI: 10.1093/rheumatology/ket275] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
60 Zellos A, Roy A, Schwarz KB. Use of oral naltrexone for severe pruritus due to cholestatic liver disease in children. J Pediatr Gastroenterol Nutr 2010;51:787-9. [PMID: 20948447 DOI: 10.1097/MPG.0b013e3181eb5ac0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
61 Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol. 2005;28:147-157. [PMID: 15879620 DOI: 10.1385/criai:28:2:147] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
62 Treeprasertsuk S, Silachamroon U, Krudsood S, Huntrup A, Suwannakudt P, Vannaphan S, Wilairatana P. Ursodeoxycholic acid and artesunate in the treatment of severe falciparum malaria patients with jaundice. J Gastroenterol Hepatol 2010;25:362-8. [PMID: 19817958 DOI: 10.1111/j.1440-1746.2009.06007.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
63 Hegade VS, Kendrick SF, Dobbins RL, Miller SR, Richards D, Storey J, Dukes G, Gilchrist K, Vallow S, Alexander GJ, Corrigan M, Hirschfield GM, Jones DE. BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial. BMC Gastroenterol 2016;16:71. [PMID: 27431238 DOI: 10.1186/s12876-016-0481-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
64 Brewer C, Wong VS. Naltrexone: report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature. Addiction Biology 2004;9:81-7. [DOI: 10.1080/13556210410001674130] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
65 Schlichting J, Leuschner U. Drug therapy of primary biliary diseases: classical and modern strategies. J Cell Mol Med 2001;5:98-115. [PMID: 12067457 DOI: 10.1111/j.1582-4934.2001.tb00144.x] [Reference Citation Analysis]
66 Prince MI, Jones DE. Primary biliary cirrhosis: new perspectives in diagnosis and treatment. Postgrad Med J 2000;76:199-206. [PMID: 10727561 DOI: 10.1136/pmj.76.894.199] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.1] [Reference Citation Analysis]
67 Hirschfield GM, Dyson JK, Alexander GJM, Chapman MH, Collier J, Hübscher S, Patanwala I, Pereira SP, Thain C, Thorburn D, Tiniakos D, Walmsley M, Webster G, Jones DEJ. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut 2018;67:1568-94. [PMID: 29593060 DOI: 10.1136/gutjnl-2017-315259] [Cited by in Crossref: 93] [Cited by in F6Publishing: 69] [Article Influence: 23.3] [Reference Citation Analysis]
68 Pongcharoen P, Fleischer A. An evidence-based review of systemic treatments for itch. Eur J Pain 2016;20:24-31. [DOI: 10.1002/ejp.766] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
69 Shawcross DL, Jalan R. Delayed opioid withdrawal-like reaction in primary biliary cirrhosis following naloxone therapy. Gastroenterology 2001;121:743-4. [PMID: 11547785 DOI: 10.1053/gast.2001.27714] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
70 Parés A, Herrera M, Avilés J, Sanz M, Mas A. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol. 2010;53:307-312. [PMID: 20580987 DOI: 10.1016/j.jhep.2010.02.031] [Cited by in Crossref: 79] [Cited by in F6Publishing: 57] [Article Influence: 6.6] [Reference Citation Analysis]
71 Novak K, Swain MG. Role of methotrexate in the treatment of chronic cholestatic disorders. Clin Liver Dis. 2008;12:81-96, viii. [PMID: 18242498 DOI: 10.1016/j.cld.2007.11.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
72 Franco J. Pruritus. Curr Treat Options Gastro 1999;2:451-6. [DOI: 10.1007/s11938-999-0048-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
73 Ekelem C, Juhasz M, Khera P, Mesinkovska NA. Utility of Naltrexone Treatment for Chronic Inflammatory Dermatologic Conditions: A Systematic Review. JAMA Dermatol 2019;155:229. [DOI: 10.1001/jamadermatol.2018.4093] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
74 Culver EL, Chapman RW. Systematic review: management options for primary sclerosing cholangitis and its variant forms - IgG4-associated cholangitis and overlap with autoimmune hepatitis. Aliment Pharmacol Ther. 2011;33:1273-1291. [PMID: 21501198 DOI: 10.1111/j.1365-2036.2011.04658.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
75 Bergasa NV. Update on the Treatment of the Pruritus of Cholestasis. Clinics in Liver Disease 2008;12:219-34. [DOI: 10.1016/j.cld.2007.11.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
76 Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology. 2000;31:1005-1013. [PMID: 10733559 DOI: 10.1053/he.2000.5984] [Cited by in Crossref: 290] [Cited by in F6Publishing: 249] [Article Influence: 13.2] [Reference Citation Analysis]
77 Gossard AA, Talwalkar JA. Cholestatic liver disease. Med Clin North Am 2014;98:73-85. [PMID: 24266915 DOI: 10.1016/j.mcna.2013.09.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
78 Levy C, Lindor KD. Current management of primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol. 2003;38 Suppl 1:S24-S37. [PMID: 12591184 DOI: 10.1016/s0168-8278(03)00006-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
79 Talwalkar JA, Lindor KD. Primary sclerosing cholangitis. Inflamm Bowel Dis. 2005;11:62-72. [PMID: 15674115 DOI: 10.1097/00054725-200501000-00009] [Cited by in Crossref: 86] [Cited by in F6Publishing: 68] [Article Influence: 5.1] [Reference Citation Analysis]
80 Esmaeili A, Nassiri Toosi M, Taher M, Merat S, Bayani J, Fruzan Karimian Z, Esmaeili A, Moazzami B, Namazi S. A Pilot Randomized, Clinical Trial of the Anti-pruritus Effect of Melatonin in Patients with Chronic Liver Disease. Iran J Pharm Res 2021;20:462-72. [PMID: 34567175 DOI: 10.22037/ijpr.2020.112942.14024] [Reference Citation Analysis]
81 Kremer AE, Feramisco J, Reeh PW, Beuers U, Oude Elferink RP. Receptors, cells and circuits involved in pruritus of systemic disorders. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2014;1842:869-92. [DOI: 10.1016/j.bbadis.2014.02.007] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
82 Rost D, Kulaksiz H, Stiehl A. Treatment of primary sclerosing cholangitis. Curr Treat Options Gastro 2007;10:111-9. [DOI: 10.1007/s11938-007-0063-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
83 Düll MM, Kremer AE. Newer Approaches to the Management of Pruritus in Cholestatic Liver Disease. Curr Hepatology Rep 2020;19:86-95. [DOI: 10.1007/s11901-020-00517-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
84 Trivella J, Levy C. Safety considerations for the management of cholestatic itch. Expert Opin Drug Saf 2021;20:915-24. [PMID: 33836644 DOI: 10.1080/14740338.2021.1915984] [Reference Citation Analysis]
85 Siemens W, Xander C, Meerpohl JJ, Antes G, Becker G. Drug treatments for pruritus in adult palliative care. Dtsch Arztebl Int 2014;111:863-70. [PMID: 25585583 DOI: 10.3238/arztebl.2014.0863] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
86 Zhao X, Wong P. Managing Sleep Disturbances in Cirrhosis. Scientifica (Cairo) 2016;2016:6576812. [PMID: 27242950 DOI: 10.1155/2016/6576812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
87 Kittanamongkolchai W, El-zoghby ZM, Eileen Hay J, Wiesner RH, Kamath PS, Larusso NF, Watt KD, Cramer CH, Leung N. Charcoal hemoperfusion in the treatment of medically refractory pruritus in cholestatic liver disease. Hepatol Int 2017;11:384-9. [DOI: 10.1007/s12072-016-9775-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
88 Luketic VA, Shiffman ML. Benign recurrent intrahepatic cholestasis. Clin Liver Dis. 2004;8:133-149, vii. [PMID: 15062197 DOI: 10.1016/s1089-3261(03)00133-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
89 Tandon P, Rowe BH, Vandermeer B, Bain VG. The Efficacy and Safety of Bile Acid Binding Agents, Opioid Antagonists, or Rifampin in the Treatment of Cholestasis-Associated Pruritus. Am J Gastroenterology 2007;102:1528-36. [DOI: 10.1111/j.1572-0241.2007.01200.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 76] [Article Influence: 7.5] [Reference Citation Analysis]
90 Cohran VC, Heubi JE. Treatment of pediatric cholestatic liver disease. Curr Treat Options Gastro 2003;6:403-15. [DOI: 10.1007/s11938-003-0043-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
91 Ferrari A, Bertolotti M, Dell'utri A, Avico U, Sternieri E. Serum time course of naltrexone and 6β-naltrexol levels during long term treatment in drug addicts. Drug and Alcohol Dependence 1998;52:211-20. [DOI: 10.1016/s0376-8716(98)00098-2] [Cited by in Crossref: 48] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
92 Brune A, Metze D, Luger TA, Ständer S. [Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non-placebo controlled administration in 133 patients]. Hautarzt 2004;55:1130-6. [PMID: 15517116 DOI: 10.1007/s00105-004-0802-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
93 Silveira MG, Lindor KD. Clinical features and management of primary sclerosing cholangitis. World J Gastroenterol 2008; 14(21): 3338-3349 [PMID: 18528931 DOI: 10.3748/wjg.14.3338] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
94 Bergasa NV. Medical palliation of the jaundiced patient with pruritus. Gastroenterol Clin North Am. 2006;35:113-123. [PMID: 16530114 DOI: 10.1016/j.gtc.2005.12.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
95 Stancil SL, Abdel-Rahman S, Wagner J. Developmental Considerations for the Use of Naltrexone in Children and Adolescents. J Pediatr Pharmacol Ther 2021;26:675-95. [PMID: 34588931 DOI: 10.5863/1551-6776-26.7.675] [Reference Citation Analysis]
96 Springer SA, Azar MM, Altice FL. HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners. Am J Drug Alcohol Abuse 2011;37:12-21. [PMID: 21171933 DOI: 10.3109/00952990.2010.540280] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
97 Kremer AE. What are new treatment concepts in systemic itch? Exp Dermatol 2019;28:1485-92. [DOI: 10.1111/exd.14024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
98 Dyson JK, Hirschfield GM, Adams DH, Beuers U, Mann DA, Lindor KD, Jones DE. Novel therapeutic targets in primary biliary cirrhosis. Nat Rev Gastroenterol Hepatol. 2015;12:147-158. [PMID: 25645973 DOI: 10.1038/nrgastro.2015.12] [Cited by in Crossref: 81] [Cited by in F6Publishing: 75] [Article Influence: 11.6] [Reference Citation Analysis]
99 Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones E. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: A controlled study. Journal of the American Academy of Dermatology 1999;41:431-4. [DOI: 10.1016/s0190-9622(99)70117-9] [Cited by in Crossref: 117] [Cited by in F6Publishing: 12] [Article Influence: 5.1] [Reference Citation Analysis]
100 Nunes ACR, Amaro P, Maçôas F, Cipriano A, Martins I, Rosa A, Pimenta I, Donato A, Freitas D. Fosinopril-induced prolonged cholestatic jaundice and pruritus: first case report: . European Journal of Gastroenterology & Hepatology 2001;13:279-82. [DOI: 10.1097/00042737-200103000-00011] [Cited by in Crossref: 31] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
101 Düll MM, Wolf K, Vetter M, Dietrich P, Neurath MF, Kremer AE. Endogenous Opioid Levels Do Not Correlate With Itch Intensity and Therapeutic Interventions in Hepatic Pruritus. Front Med (Lausanne) 2021;8:641163. [PMID: 33937284 DOI: 10.3389/fmed.2021.641163] [Reference Citation Analysis]
102 Metze D, Reimann S, Luger TA. Effective Treatment of Pruritus with Naltrexone, an Orally Active Opiate Antagonist. Annals of the New York Academy of Sciences 1999;885:430-2. [DOI: 10.1111/j.1749-6632.1999.tb08705.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
103 Szalay F. Treatment of primary biliary cirrhosis. J Physiol Paris 2001;95:407-12. [PMID: 11595467 DOI: 10.1016/s0928-4257(01)00055-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
104 Bergasa NV. Pruritus in primary biliary cirrhosis: pathogenesis and therapy. Clin Liver Dis. 2008;12:385-406; x. [PMID: 18456187 DOI: 10.1016/j.cld.2008.02.013] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
105 Lazaridis KN, Lindor KD. Primary biliary cirrhosis. Curr Treat Options Gastro 1999;2:473-80. [DOI: 10.1007/s11938-999-0051-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
106 Lee YM, Kaplan MM. Management of primary sclerosing cholangitis. Am J Gastroenterol. 2002;97:528-534. [PMID: 11922543 DOI: 10.1111/j.1572-0241.2002.05585.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 2.4] [Reference Citation Analysis]
107 Krok KL, Munoz SJ. Management of autoimmune and cholestatic liver disorders. Clin Liver Dis 2009;13:295-316. [PMID: 19442920 DOI: 10.1016/j.cld.2009.02.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
108 El-Shabrawi MH, Kamal NM. Medical management of chronic liver diseases (CLD) in children (part II): focus on the complications of CLD, and CLD that require special considerations. Paediatr Drugs. 2011;13:371-383. [PMID: 21999650 DOI: 10.2165/11591620-000000000-00000] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
109 Neuberger J, Jones EA. Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy. Eur J Gastroenterol Hepatol. 2001;13:1393-1394. [PMID: 11692070 DOI: 10.1097/00042737-200111000-00022] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
110 Jones EA, Dekker LR. Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis. Gastroenterology 2000;118:431-2. [PMID: 10648471 DOI: 10.1016/s0016-5085(00)70225-3] [Cited by in Crossref: 53] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
111 Sharma P, Rakela J. Management of pre-liver transplantation patient?Part 2. Liver Transpl 2005;11:249-60. [DOI: 10.1002/lt.20379] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
112 Malekzad F, Arbabi M, Mohtasham N, Toosi P, Jaberian M, Mohajer M, Mohammadi M, Roodsari M, Nasiri S. Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study. Journal of the European Academy of Dermatology and Venereology 2009;23:948-50. [DOI: 10.1111/j.1468-3083.2009.03129.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
113 Ng VL, Balistreri WF. Treatment options for chronic cholestasis in infancy and childhood. Curr Treat Options Gastro 2005;8:419-30. [DOI: 10.1007/s11938-005-0045-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
114 Kambia K, Bah S, Dine T, Azar R, Odou P, Gressier B, Luyckx M, Brunet C, Ballester L, Cazin M, Cazin JC. High-performance liquid chromatographic determination of naltrexone in plasma of hemodialysis patients. Biomed Chromatogr 2000;14:151-5. [DOI: 10.1002/1099-0801(200005)14:3<151::aid-bmc941>3.0.co;2-e] [Cited by in Crossref: 14] [Article Influence: 0.6] [Reference Citation Analysis]
115 Howard P, Twycross R, Grove G, Charlesworth S, Mihalyo M, Wilcock A. Rifampin (INN Rifampicin). Journal of Pain and Symptom Management 2015;50:891-5. [DOI: 10.1016/j.jpainsymman.2015.09.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
116 Schmelz M, Schmidt R, Weidner C, Hilliges M, Torebjork HE, Handwerker HO. Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. J Neurophysiol. 2003;89:2441-2448. [PMID: 12611975 DOI: 10.1152/jn.01139.2002] [Cited by in Crossref: 256] [Cited by in F6Publishing: 225] [Article Influence: 13.5] [Reference Citation Analysis]
117 Villamil AG, Bandi JC, Galdame OA, Gerona S, Gadano AC. Efficacy of lidocaine in the treatment of pruritus in patients with chronic cholestatic liver diseases. Am J Med. 2005;118:1160-1163. [PMID: 16194649 DOI: 10.1016/j.amjmed.2005.05.031] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
118 Lidstone V, Thorns A. Pruritus in cancer patients. Cancer Treatment Reviews 2001;27:305-12. [DOI: 10.1053/ctrv.2001.0231] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
119 Feramisco JD, Berger TG, Steinhoff M. Innovative management of pruritus. Dermatol Clin 2010;28:467-78. [PMID: 20510757 DOI: 10.1016/j.det.2010.03.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
120 Umeuchi H, Kawashima Y, Aoki CA, Kurokawa T, Nakao K, Itoh M, Kikuchi K, Kato T, Okano K, Gershwin ME, Miyakawa H. Spontaneous scratching behavior in MRL/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel κ-opioid receptor agonist nalfurafine hydrochloride. European Journal of Pharmacology 2005;518:133-9. [DOI: 10.1016/j.ejphar.2005.06.019] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
121 Metze D, Reimann S, Beissert S, Luger T. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. Journal of the American Academy of Dermatology 1999;41:533-9. [DOI: 10.1016/s0190-9622(99)80048-6] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
122 Tischendorf JJ, Geier A, Trautwein C. Current diagnosis and management of primary sclerosing cholangitis. Liver Transpl. 2008;14:735-746. [PMID: 18508363 DOI: 10.1002/lt.21456] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
123 Yoshida EM, Méndez-sánchez N. Hepatology Highlights. Annals of Hepatology 2010;9:117-9. [DOI: 10.1016/s1665-2681(19)31649-7] [Reference Citation Analysis]
124 Levy C, Lindor KD. Management of primary biliary cirrhosis. Curr Treat Options Gastro 2003;6:493-8. [DOI: 10.1007/s11938-003-0051-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
125 Kuiper EM, van Erpecum KJ, Beuers U, Hansen BE, Thio HB, de Man RA, Janssen HL, van Buuren HR. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology 2010;52:1334-40. [PMID: 20683930 DOI: 10.1002/hep.23821] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 6.0] [Reference Citation Analysis]
126 Gingold AR, Bergasa NV. The cannabinoid agonist WIN 55, 212-2 increases nociception threshold in cholestatic rats: implications for the treatment of the pruritus of cholestasis. Life Sciences 2003;73:2741-7. [DOI: 10.1016/s0024-3205(03)00668-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
127 Rajagopalan M, Saraswat A, Godse K, Shankar DS, Kandhari S, Shenoi SD, Tahiliani S, Zawar VV. Diagnosis and Management of Chronic Pruritus: An Expert Consensus Review. Indian J Dermatol 2017;62:7-17. [PMID: 28216719 DOI: 10.4103/0019-5154.198036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
128 Krishnan A, Koo J. Psyche, opioids, and itch: therapeutic consequences: Psyche, opioids, and itch. Dermatologic Therapy 2005;18:314-22. [DOI: 10.1111/j.1529-8019.2005.00038.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
129 Mansour-Ghanaei F, Taheri A, Froutan H, Ghofrani H, Nasiri-Toosi M, Bagherzadeh AH, Farahvash MJ, Mirmomen S, Ebrahimi-Dariani N, Farhangi E, Pourrasouli Z. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 2006; 12(7): 1125-1128 [PMID: 16534857 DOI: 10.3748/wjg.v12.i7.1125] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
130 Imam MH, Gossard AA, Sinakos E, Lindor KD. Pathogenesis and management of pruritus in cholestatic liver disease. J Gastroenterol Hepatol. 2012;27:1150-1158. [PMID: 22413872 DOI: 10.1111/j.1440-1746.2012.07109.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
131 Summey BT. Pruritus. Palliative Medicine. Elsevier; 2009. pp. 910-3. [DOI: 10.1016/b978-0-323-05674-8.50170-5] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
132 Bergasa NV, Mehlman JK, Jones EA. Pruritus and fatigue in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol. 2000;14:643-655. [PMID: 10976020 DOI: 10.1053/bega.2000.0109] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 2.0] [Reference Citation Analysis]
133 Cisneros-garza LE, Muñoz-ramírez MDR, Muñoz-espinoza LE, Velasco JAVR, Moreno-alcántar R, Marín-lópez E, Méndez-sánchez N. The molecular adsorbent recirculating system as a liver support system. Summary of Mexican experience. Annals of Hepatology 2014;13:240-7. [DOI: 10.1016/s1665-2681(19)30887-7] [Cited by in Crossref: 13] [Article Influence: 1.6] [Reference Citation Analysis]
134 Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol. 2005;28:147-157. [PMID: 15879620 DOI: 10.1385/criai:] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
135 Carrion AF, Rosen JD, Levy C. Understanding and Treating Pruritus in Primary Biliary Cholangitis. Clinics in Liver Disease 2018;22:517-32. [DOI: 10.1016/j.cld.2018.03.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
136 Bergasa NV, Schmitt JM, Talbot TL, Alling DW, Swain MG, Turner ML, Jenkins JB, Jones EA. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology. 1998;27:679-684. [PMID: 9500694 DOI: 10.1002/hep.510270307] [Cited by in Crossref: 127] [Cited by in F6Publishing: 102] [Article Influence: 5.3] [Reference Citation Analysis]
137 Bolier R, de Vries ES, Parés A, Helder J, Kemper EM, Zwinderman K, Elferink RPO, Beuers U; Netherlands Association for the Study of the Liver (NASL) Cholestatic Liver Diseases Study Group. Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial. Trials 2017;18:230. [PMID: 28535810 DOI: 10.1186/s13063-017-1966-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
138 Hohl CM, Wong JK, Harlos MS. Methylnaltrexone to Palliate Pruritus in Terminal Hepatic Disease. J Palliat Care 2015;31:124-6. [PMID: 26201215 DOI: 10.1177/082585971503100209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
139 Lonsdale-eccles A, Carmichael AJ. Treatment of Pruritus Associated with Systemic Disorders in the Elderly: A Review of the Role of New Therapies. Drugs & Aging 2003;20:197-208. [DOI: 10.2165/00002512-200320030-00004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
140 Phan NQ, Bernhard JD, Luger TA, Ständer S. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. J Am Acad Dermatol. 2010;63:680-688. [PMID: 20462660 DOI: 10.1016/j.jaad.2009.08.052] [Cited by in Crossref: 109] [Cited by in F6Publishing: 77] [Article Influence: 9.1] [Reference Citation Analysis]
141 Saab S, Han S, Martin P. LIVER TRANSPLANTATION. Clinics in Liver Disease 2000;4:513-32. [DOI: 10.1016/s1089-3261(05)70124-0] [Cited by in Crossref: 8] [Article Influence: 0.4] [Reference Citation Analysis]
142 Levy C, Lindor KD. Drug-induced cholestasis. Clinics in Liver Disease 2003;7:311-30. [DOI: 10.1016/s1089-3261(03)00032-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
143 Bergasa NV. An approach to the management of the pruritus of cholestasis. Clinics in Liver Disease 2004;8:55-66. [DOI: 10.1016/s1089-3261(03)00128-4] [Cited by in Crossref: 9] [Article Influence: 0.5] [Reference Citation Analysis]
144 Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut. 2002;50:436-439. [PMID: 11839728 DOI: 10.1136/gut.50.3.436] [Cited by in Crossref: 140] [Cited by in F6Publishing: 111] [Article Influence: 7.0] [Reference Citation Analysis]
145 Faramarzi N, Abbasi A, Tavangar SM, Mazouchi M, Dehpour AR. Opioid receptor antagonist promotes angiogenesis in bile duct ligated rats. J Gastroenterol Hepatol 2009;24:1226-9. [PMID: 19486259 DOI: 10.1111/j.1440-1746.2009.05794.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
146 Xander C, Meerpohl JJ, Galandi D, Buroh S, Schwarzer G, Antes G, Becker G. Pharmacological interventions for pruritus in adult palliative care patients. Cochrane Database Syst Rev 2013;:CD008320. [PMID: 23749733 DOI: 10.1002/14651858.CD008320.pub2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
147 Krajnik M, Zylicz Z. Understanding Pruritus in Systemic Disease. Journal of Pain and Symptom Management 2001;21:151-68. [DOI: 10.1016/s0885-3924(00)00256-6] [Cited by in Crossref: 91] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
148 Silvagni E, Colì L, Stagni B, Stefoni S, Bolondi L. A case of intractable pruritus in Turner's syndrome successfully treated with molecular adsorbent recirculating system. Intern Emerg Med 2008;3:65-7. [PMID: 18273566 DOI: 10.1007/s11739-008-0094-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
149 Bergasa NV. Studying pruritus in the 21st century. Clinical Gastroenterology and Hepatology 2003;1:249-51. [DOI: 10.1016/s1542-3565(03)00140-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
150 Terg R, Coronel E, Sordá J, Muñoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002;37:717-22. [PMID: 12445410 DOI: 10.1016/s0168-8278(02)00318-5] [Cited by in Crossref: 113] [Cited by in F6Publishing: 22] [Article Influence: 5.9] [Reference Citation Analysis]
151 Kremer AE, Oude Elferink RP, Beuers U. Pathophysiology and current management of pruritus in liver disease. Clin Res Hepatol Gastroenterol. 2011;35:89-97. [PMID: 21809485 DOI: 10.1016/j.clinre.2010.10.007] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
152 Mela M, Mancuso A, Burroughs AK. Review article: pruritus in cholestatic and other liver diseases. Aliment Pharmacol Ther. 2003;17:857-870. [PMID: 12656688 DOI: 10.1046/j.1365-2036.2003.01458.x] [Cited by in Crossref: 89] [Cited by in F6Publishing: 64] [Article Influence: 4.7] [Reference Citation Analysis]
153 Bergasa NV. Pruritus and fatigue in primary biliary cirrhosis. Clin Liver Dis. 2003;7:879-900. [PMID: 14594135 DOI: 10.1016/s1089-3261(03)00105-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
154 Bhalerao A, Mannu GS. Management of pruritus in chronic liver disease. Dermatol Res Pract 2015;2015:295891. [PMID: 25861254 DOI: 10.1155/2015/295891] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
155 Squires RH. End-stage liver disease in children. Curr Treat Options Gastro 2001;4:409-21. [DOI: 10.1007/s11938-001-0006-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
156 Jones E, Zylicz Z. Treatment of Pruritus Caused by Cholestasis with Opioid Antagonists. Journal of Palliative Medicine 2005;8:1290-4. [DOI: 10.1089/jpm.2005.8.1290] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
157 Patel SP, Vasavda C, Ho B, Meixiong J, Dong X, Kwatra SG. Cholestatic pruritus: Emerging mechanisms and therapeutics. J Am Acad Dermatol 2019;81:1371-8. [PMID: 31009666 DOI: 10.1016/j.jaad.2019.04.035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
158 Gossard AA. Care of the cholestatic patient. Clin Liver Dis 2013;17:331-44. [PMID: 23540506 DOI: 10.1016/j.cld.2012.11.005] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
159 Cotes ME, Swerlick RA. Practical guidelines for the use of steroid-sparing agents in the treatment of chronic pruritus. Dermatol Ther 2013;26:120-34. [PMID: 23551369 DOI: 10.1111/dth.12026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
160 Cherny NI. Taking care of the terminally ill cancer patient: management of gastrointestinal symptoms in patients with advanced cancer. Ann Oncol 2004;15 Suppl 4:iv205-13. [PMID: 15477309 DOI: 10.1093/annonc/mdh928] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
161 Barnett V, Twycross R, Mihalyo M, Wilcock A. Opioid Antagonists. Journal of Pain and Symptom Management 2014;47:341-52. [DOI: 10.1016/j.jpainsymman.2013.12.223] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
162 Lazaridis KN, Lindor KD. Management of primary biliary cirrhosis: From diagnosis to end-stage disease. Curr Gastroenterol Rep 2000;2:94-8. [DOI: 10.1007/s11894-000-0091-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
163 Olson GA, Olson RD, Vaccarino AL, Kastin AJ. Endogenous opiates: 1997. Peptides 1998;19:1791-843. [DOI: 10.1016/s0196-9781(98)00137-5] [Cited by in Crossref: 53] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
164 Mani AR, Rasool R, Montagnese S, Dehpour AR. Endogenous opioids and liver disease. Scandinavian Journal of Gastroenterology 2009;41:1-11. [DOI: 10.1080/00365520500287533] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
165 Bergasa NV. Pruritus in chronic liver disease: mechanisms and treatment. Curr Gastroenterol Rep 2004;6:10-6. [PMID: 14720448 DOI: 10.1007/s11894-004-0020-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
166 Bates JJ, Foss JF, Murphy DB. Are Peripheral Opioid Antagonists the Solution to Opioid Side Effects?: . Anesthesia & Analgesia. [DOI: 10.1213/01.ane.0000090147.97636.77] [Cited by in Crossref: 41] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
167 Crosignani A, Battezzati PM, Invernizzi P, Selmi C, Prina E, Podda M. Clinical features and management of primary biliary cirrhosis. World J Gastroenterol 2008; 14(21): 3313-3327 [PMID: 18528929 DOI: 10.3748/wjg.14.3313] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
168 Jones E. Trials of opiate antagonists for the pruritus of cholestasis: primary efficacy endpoints and opioid withdrawal-like reactions. Journal of Hepatology 2002;37:863-5. [DOI: 10.1016/s0168-8278(02)00347-1] [Cited by in Crossref: 11] [Article Influence: 0.6] [Reference Citation Analysis]
169 Bergasa NV. The pruritus of cholestasis. J Hepatol. 2005;43:1078-1088. [PMID: 16253381 DOI: 10.1016/j.jhep.2005.09.004] [Cited by in Crossref: 82] [Cited by in F6Publishing: 58] [Article Influence: 4.8] [Reference Citation Analysis]
170 Lisboa LF, Asthana S, Kremer A, Swain M, Bagshaw SM, Gibney N, Karvellas CJ. Blood cytokine, chemokine and gene expression in cholestasis patients with intractable pruritis treated with a molecular adsorbent recirculating system: a case series. Can J Gastroenterol 2012;26:799-805. [PMID: 23166903 DOI: 10.1155/2012/623862] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
171 Friedman JD, Dello Buono FA. Opioid antagonists in the treatment of opioid-induced constipation and pruritus. Ann Pharmacother. 2001;35:85-91. [PMID: 11197589 DOI: 10.1345/aph.10121] [Cited by in Crossref: 64] [Cited by in F6Publishing: 51] [Article Influence: 3.0] [Reference Citation Analysis]
172 Heyer G, Groene D, Martus P. Efficacy of naltrexone on acetylcholine-induced alloknesis in atopic eczema: NAL on acetylcholine-induced alloknesis in AE. Experimental Dermatology 2002;11:448-55. [DOI: 10.1034/j.1600-0625.2002.110508.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
173 Bergasa NV. Treatment of the pruritus of cholestasis. Curr Treat Options Gastro 2004;7:501-8. [DOI: 10.1007/s11938-004-0009-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
174 Bunchorntavakul C, Reddy KR. Pruritus in chronic cholestatic liver disease. Clin Liver Dis 2012;16:331-46. [PMID: 22541702 DOI: 10.1016/j.cld.2012.03.010] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
175 Stauber R, Krisper P, Zollner G, Iberer F, Beuers U, Trauner M. Extracorporeal Albumin Dialysis in a Patient with Primary Sclerosing Cholangitis: Effect on Pruritus and Bile Acid Profile. Int J Artif Organs 2004;27:342-4. [DOI: 10.1177/039139880402700411] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
176 Sikora M, Rakowska A, Olszewska M, Rudnicka L. The Use of Naltrexone in Dermatology. Current Evidence and Future Directions. Curr Drug Targets 2019;20:1058-67. [PMID: 30887922 DOI: 10.2174/1389450120666190318121122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
177 Kremer AE, Beuers U, Oude-Elferink RP, Pusl T. Pathogenesis and treatment of pruritus in cholestasis. Drugs. 2008;68:2163-2182. [PMID: 18840005 DOI: 10.2165/00003495-200868150-00006] [Cited by in Crossref: 77] [Cited by in F6Publishing: 58] [Article Influence: 5.9] [Reference Citation Analysis]
178 Bigliardi-qi M, Gaveriaux-ruff C, Pfaltz K, Bady P, Baumann T, Rufli T, Kieffer BL, Bigliardi PL. Deletion of μ- and κ-Opioid Receptors in Mice Changes Epidermal Hypertrophy, Density of Peripheral Nerve Endings, and Itch Behavior. Journal of Investigative Dermatology 2007;127:1479-88. [DOI: 10.1038/sj.jid.5700661] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]